Adebrelimab plus Apatinib

Phase 2Small molecule

PPeking University Cancer Hospital & Institute

Adebrelimab plus Apatinib is one of 93 small molecule programs targeting Chemoradiotherapy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChemoradiotherapyNot yet recruiting

Maintenance TherapyNot yet recruiting

First-Line TreatmentRecruiting

Esophageal Squamous CarcinomaRecruiting

ChemoradiotherapyPhase 2

Not yet recruiting

Maintenance TherapyPhase 2

Not yet recruiting

First-Line TreatmentPhase 2

Recruiting

Esophageal Squamous CarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

74 competitors in First-Line Treatment

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

4 2

Lexapro

AbbVie

Phase 3

1 3

Tuoyi

SSun Yat-sen University

Phase 3

6 4

Vepesid

AAvyxa

Phase 3

3 5

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 6

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

2 7

Lithobid

SSolvay Pharmaceuticals

Phase 3

1 8

Effexor

WWyeth-Lederle Vaccines

Phase 3

1 9

Wellbutrin

GGlaxo Dba Glaxosmithkline

Phase 3

1 10

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Esophageal Squamous Carcinoma

NCT06869213

Q1 2028

Phase 2Recruiting

First-Line Treatment

NCT06360042

Q3 2028

Phase 2Not yet recruiting

Maintenance Therapy

NCT07381543

Phase 2Not yet recruiting

Chemoradiotherapy

NCT07200154

Clinical

Trials by Indication[1]

Maintenance Therapy1 trial

Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone

Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT07381543·76 enrolled

Chemoradiotherapy1 trial

Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC

Not yet recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT07200154·30 enrolled

Esophageal Squamous Carcinoma1 trial

A Single-arm, Open, Single-center Exploratory Study of Adebrelimab (SHR-1316) in Combination With Chemotherapy for the Perioperative Treatment of Locally Advanced Resectable Esophageal Squamous Carcinoma

Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT06869213·30 enrolled

First-line Treatment1 trial

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT06360042·111 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Adebrelimab plus Apatinib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adebrelimab plus Apatinib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adebrelimab plus Apatinib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University Cancer Hospital & Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPeking University Cancer Hospital & Institute

Adebrelimab plus Apatinib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q1 2028

Q3 2028

Trials by Indication[1]

Maintenance Therapy1 trial

Chemoradiotherapy1 trial

Esophageal Squamous Carcinoma1 trial

First-line Treatment1 trial

References

Drug Info

Quick Facts

Related News